ClinicalTrials.gg
WithdrawnNCT04264806Updated May 20, 2022

A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)

A Phase 2 interventional study of Azacitidine and Cusatuzumab in Myelodysplastic Syndromes and Leukemia, Myelomonocytic, Chronic, sponsored by Janssen Research & Development, LLC. Withdrawn at 73 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-20.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Why this study was withdrawn
The cusatuzumab MDS strategy is under revision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 130 studies testing azacitidine in Myelodysplastic Syndromes — 13 open to participants now, 25 under way, 3 of them phase 3. Azacitidine · Myelodysplastic Syndromes.

Enrollment
120th of 126
0 · median 38
Started
2021
with 3 others
Phase 2
63 of 130
5 open now
Registered
105th of 130
by date

Among the 130 studies testing azacitidine in Myelodysplastic Syndromes, this one is the 120th largest by enrollment of the 126 interventional ones that give a count, is one of 4 that started in 2021, is one of 63 in phase 2, and was the 105th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

13 of the 130 studies testing azacitidine in Myelodysplastic Syndromes are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About azacitidine

Azacitidine: first FDA approval 2004 (VIDAZA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies testing azacitidine in Myelodysplastic Syndromes, or all of them as a file.
02

Study summary

The purpose of the study is to compare overall response rate (ORR) between treatment groups in participants with higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) who are not eligible for Hematopoietic Stem Cell Transplantation (HSCT).

Read the detailed description

Cusatuzumab (also known as JNJ-74494550 and ARGX-110) is a humanized monoclonal antibody of camelid origin that binds with high affinity to human Cluster of Differentiation 70 (CD70). Azacitidine (an Hypomethylating agent [HMA]) is approved for the treatment of higher-risk MDS in the United States (US) and the European Union (EU). Both approvals are based on data showing decreased transfusion burden, delayed progression to acute myeloid leukemia (AML), improved quality of life, and extended survival. It is hypothesized that the addition of cusatuzumab to azacitidine will result in an improvement in overall response rate (ORR) compared with azacitidine alone in participants with higher-risk MDS or CMML.

03

Conditions studied

  • Myelodysplastic Syndromes
  • Leukemia, Myelomonocytic, Chronic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of de novo or secondary higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) per World Health Organization (WHO) 2016 criteria
  • At study entry, higher-risk MDS (intermediate, high, and very high risk MDS per Revised International Prognostic Scoring System [IPSS R]) OR higher-risk CMML (intermediate-2 or high risk CMML per CMML-specific Prognostic Scoring System [CPSS-Mol]). Participants with previous lower-risk MDS or CMML that has evolved to higher-risk MDS or CMML are eligible
  • At study entry, not a candidate for Hematopoietic Stem Cell Transplantation ()
  • (ECOG) performance status score of 0, 1, or 2
  • Adequate liver and renal function defined as follows: (AST) or alanine aminotransferase (ALT) less than (\<) 3 * (ULN); Total less than or equal to (\<=) 1.5 * ULN, unless bilirubin rise is due to Gilbert's syndrome or of non hepatic origin; and (CrCl) greater than (>) 30 milliliter per minute per 1.73 square meters (mL/min/1.73 m\^2) (by Modification of Diet in Renal Disease formula)

Exclusion criteria

Exclusion Criteria:

  • Received prior or any prior treatment, including hypomethylating agent (HMAs), for higher-risk MDS or CMML. Prior supportive therapies including transfusion and growth factors are acceptable
  • Received prior treatment with cusatuzumab
  • Presence of the breakpoint cluster region protein-Abelson murine leukemia (bcr-abl) rearrangement
  • Received a live, attenuated vaccine within 4 weeks prior to initiation of study drug
  • Any active systemic infection
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Azacitidine: Participants with MDS or CMML

    Participants with higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) will receive azacitidine 75 milligram per meter square (mg/m\^2) body surface area (BSA) subcutaneously or Intravenously per local label on Days 1 through Day 7 of each 28-day cycle. Participants will be treated until disease progression; relapse from complete remission (CR), partial remission (PR), or marrow complete remission (mCR); transformation to acute myeloid leukemia (AML); death; or unacceptable toxicity.

    Drug: Azacitidine

  • Experimental
    Azacitidine and Cusatuzumab: Participants with MDS or CMML

    Participants with higher-risk MDS or CMML will receive azacitidine 75 mg/m\^2 BSA subcutaneously or Intravenously per local label on Days 1 through 7 and cusatuzumab 20 mg/kg IV on Days 3 and 17 of each 28-day cycle. Participants will be treated until disease progression; relapse from CR, PR, mCR; transformation to AML; death; or unacceptable toxicity.

    Drug: Azacitidine · Drug: Cusatuzumab

Interventions

  • Participants will receive subcutaneous (SC) or intravenous (IV) injection of Azacitidine 75 mg/m\^2.

  • Participants will receive SC or IV injection of Cusatuzumab 20 mg/kg.

    Also known as: JNJ-74494550,, ARGX-110

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    ORR is a composite of complete remission (CR), partial remission (PR) and marrow complete remission (mCR) as per modified International Working Group (IWG) criteria.

    Time frame: Up to 4 years

Secondary outcomes

  1. Percentage of Participants Achieving Complete Remission (CR)

    Percentage of participants achieving CR as per IWG criteria will be reported.

    Time frame: Up to 4 years

  2. Percentage of Participants who Achieve Transfusion Independence

    Percentage of participants who achieve transfusion independence will be reported. Transfusion independence is defined as a period of greater than or equal to (\>=) 56 consecutive days with no transfusion occurring between the first and last dose of study drug +30 days.

    Time frame: Up to 4 years

  3. Time to Transformation of Participants to Acute Myeloid Leukemia (AML)

    Time to transformation of participants to AML will be reported. Transformation to AML is defined as \>= 20% bone marrow blasts.

    Time frame: Up to 4 years

  4. Progression Free Survival (PFS)

    PFS is defined as the time from randomization to disease progression; relapse from CR, PR, or mCR; or death from any cause.

    Time frame: Up to 4 years

  5. Overall Survival (OS)

    OS is defined as the time from randomization to death.

    Time frame: Up to 4 years

  6. Hematologic Improvement Rate

    Hematologic improvement rate is defined as erythroid response (pretreatment, less than (\<) 11 g/dL; hemoglobin \>= 1.5 g/dL; relevant reduction of units of RBC transfusions by an absolute number of \>= 4 Red blood cell (RBC) transfusions/8 weeks compared with the pretreatment transfusion number in the previous 8 weeks. Only RBC transfusions given for a hemoglobin of \<= 9.0 g/dL pretreatment will count in the RBC transfusion response evaluation; platelet response (pretreatment \<100\*10\^9/L); absolute increase of \>= 30\*109/L for participants starting with \>20\*10\^9/L platelets; increase to \>20\*109/L and by \>= 100% for participants starting with \<= 20\*109/L platelets; Neutrophil response (pretreatment \<1.0×10\^9/L); and at least 100% increase and an absolute increase of \>0.5\*10\^9/L.

    Time frame: Up to 4 years

  7. Percentage of Participants With Adverse Events (AEs) as a Measure of Safety and Tolerability

    An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.

    Time frame: Up to 4 years

  8. Percentage of Participants With Clinically Significant Abnormalities in Laboratory Parameters

    Percentage of participants with clinically significant abnormalities in laboratory parameters will be reported.

    Time frame: Up to 4 years

  9. Area Under the Serum Concentration-Time Curve Within Timespan t1 to t2 (AUC[t1-t2]) of Cusatuzumab

    The AUC(t1-t2) is the area under the serum concentration-time curve within timespan t1 to t2.

    Time frame: Cycle 1: Day 3,17 (predose, end of infusion [EOI] postdose), Day 4 (24 hours postdose) Cycle 2, 3, 4, 8, 11: Day 3 (predose, EOI postdose); Cycle 4 Day 21 to Cycle 5: Day 1(at disease evaluation); and end of treatment (EOT) [up to 4 years])

  10. Maximum Serum Concentration (Cmax) of Cusatuzumab

    Cmax is the maximum observed serum concentration.

    Time frame: Cycle 1: Day 3,17 (predose, end of infusion [EOI] postdose), Day 4 (24 hours postdose) Cycle 2, 3, 4, 8, 11: Day 3 (predose, EOI postdose); Cycle 4 Day 21 to Cycle 5: Day 1(at disease evaluation); and end of treatment (EOT) [up to 4 years])

  11. Minimum Serum Concentration (Cmin) of Cusatuzumab

    Cmin is the minimum observed serum concentration.

    Time frame: Cycle 1: Day 3,17 (predose, end of infusion [EOI] postdose), Day 4 (24 hours postdose) Cycle 2, 3, 4, 8, 11: Day 3 (predose, EOI postdose); Cycle 4 Day 21 to Cycle 5: Day 1(at disease evaluation); and end of treatment (EOT) [up to 4 years])

  12. Elimination Half-Life (t1/2) of Cusatuzumab

    T1/2 is the time measured for the serum concentration to decrease by 1 half to its original concentration. It is associated with the terminal slope of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).

    Time frame: Cycle 1: Day 3,17 (predose, end of infusion [EOI] postdose), Day 4 (24 hours postdose) Cycle 2, 3, 4, 8, 11: Day 3 (predose, EOI postdose); Cycle 4 Day 21 to Cycle 5: Day 1(at disease evaluation); and end of treatment (EOT) [up to 4 years])

  13. Systemic Clearance (CL) of Cusatuzumab

    CL is a quantitative measure of the rate at which a drug substance is removed from the body.

    Time frame: Cycle 1: Day 3,17 (predose, end of infusion [EOI] postdose), Day 4 (24 hours postdose) Cycle 2, 3, 4, 8, 11: Day 3 (predose, EOI postdose); Cycle 4 Day 21 to Cycle 5: Day 1(at disease evaluation); and end of treatment (EOT) [up to 4 years])

  14. Volume of Distribution (Vz) of Cusatuzumab

    The Vz is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug.

    Time frame: Cycle 1: Day 3,17 (predose, end of infusion [EOI] postdose), Day 4 (24 hours postdose) Cycle 2, 3, 4, 8, 11: Day 3 (predose, EOI postdose); Cycle 4 Day 21 to Cycle 5: Day 1(at disease evaluation); and end of treatment (EOT) [up to 4 years])

  15. Number of Participants with Developed Antidrug Antibodies to Cusatuzumab

    Venous blood samples are analyzed for presence of antidrug antibodies to cusatuzumab. Participants with titer of confirmed positive samples for cusatuzumab antibodies are reported.

    Time frame: Cycle 1: Day 3 (Predose); Cycle 1: Day 17 (Predose); Cycle 2: Day 3 (Predose); Cycle 8 and 11: Day 3 (Predose) and EOT (up to 4 years)

  16. Percentage of Participants Achieving Complete Remission (CR) and Partial Remission (PR)

    Percentage of participants achieving CR and PR as per IWG criteria will be reported.

    Time frame: Up to 4 years

  17. Time to response

    Time to response for participants who achieved CR, PR and mCR responses, defined as time from randomization to achieving the first response of CR, PR, or mCR as per modified IWG criteria.

    Time frame: Up to 4 years

  18. Duration of response

    Time from achieving the first response of CR, PR, or mCR to relapse or death from any cause for those participants who responded.

    Time frame: Up to 4 years

  19. Percentage of Participants With Clinically Meaningful Improvement in Functional Assessment of Cancer Therapy - Anemia Trial Outcome Index (FACT-An TOI) Total Score

    FACT-An is a scale in Functional Assessment of Chronic Illness Therapy Measurement System. It consists of Functional Assessment of Cancer Therapy (general version; FACT-G) and 20 questions labeled "additional concerns" that measure anemia/fatigue. FACT-G is 27-item compilation of general questions divided into 4 primary quality of life domains: physical well-being, social/family well-being, emotional wellbeing, and functional well-being. Participants will be asked to rate scale items as it applies to past 7 days, on 5-point scale (0=Not at all, 1=A little bit, 2=Somewhat, 3=Quite a bit, 4=Very much). Negatively stated items will be reversed by subtracting the response from 4. After reversing the proper items, items are summed to a total to generate a score on (sub)scale. A summary Trial Outcome Index total score (FACT An TOI) will be calculated by summing physical well being, functional well being, and anemia symptoms subscales and higher is the score better is the quality of life.

    Time frame: Up to 4 years

07

Study locations

73 sites
  • St Vincents Hospital Sydney
    Darlinghurst, 2010, Australia
  • St Vincents Hospital Melbourne
    Fitzroy, 3065, Australia
  • Peter MacCallum Cancer Institute
    Melbourne, Australia
  • Royal Perth Hospital
    Perth, 6000, Australia
  • Westmead Hospital
    Westmead, 2145, Australia
  • Wollongong Hospital
    Wollongong, 2500, Australia
  • Hospital Erasto Gaertner- Liga Paranaense de Combate ao Câncer
    Curitiba, 81520-060, Brazil
  • Cepon - Centro De Pesquisas Oncologicas
    Florianopolis, 88034-000, Brazil
  • Liga Norte Riograndense Contra O Cancer
    Natal, 59062-000, Brazil
  • Hospital de Clínicas de Porto Alegre
    Porto Alegre, 90035-903, Brazil
  • Instituto do cancer -COR -Hospital Mae de Deus
    Porto Alegre, 90110-270, Brazil
  • Oncoclínicas
    Rio De Janeiro, 22250-905, Brazil
  • Hospital de Base de São José do Rio Preto
    São José do Rio Preto, 15090-000, Brazil
  • Hospital Paulistano
    São Paulo, 01321-001, Brazil
  • Instituto D'Or de Pesquisa e Ensino (IDOR)
    São Paulo, 4501000, Brazil
  • CHU d'Angers
    Angers, 49933, France
  • Hopital Saint Vincent de Paul
    Lille, 59020, France
  • CHU de Limoges, Hopital Dupuytren
    Limoges, 87042, France
  • Hôpital de La Conception
    Marseille, 13005, France
  • CHU de Nice Hopital de l Archet
    Nice, 06200, France
  • Hopital Saint-Louis
    Paris Cedex 10, 75475, France
  • Hopital Cochin APHP
    Paris, 75, 75674, France
  • CHRU Tours Hôpital Bretonneau
    Tours, 37000, France
  • CHU de Nancy_ Hôpital Brabois
    Vandoeuvre Les Nancy, 54500, France
  • Universitatsklinikum Carl Gustav Carcus Dresden
    Dresden, 01307, Germany
  • Universitätsklinik Freiburg
    Freiburg Im Breisgau, 79106, Germany
  • Medizinische Hochschule Hannover
    Hannover, 30625, Germany
  • Universitatsklinikum Leipzig
    Leipzig, 04103, Germany
  • Klinikum rechts der Isar an der Technischen Universität München
    München, 81675, Germany
  • Universitaetsklinikum Ulm
    Ulm, 89081, Germany
  • Policlinico Sant'Orsola Malpighi
    Bologna, 40138, Italy
  • Azienda Ospedaliero Universitaria di Ferrara
    Cona, 44124, Italy
  • Università del Piemonte Orientale - Ospedale Maggiore della Carità di Novara
    Novara, 28100, Italy
  • Aou San Luigi Gonzaga
    Orbassano, 10043, Italy
  • Grande Ospedale Metropolitano 'Bianchi-Melacrino-Morelli' Reggio Calabria
    Reggio Calabria, 89124, Italy
  • Fondazione Policlinico Tor Vergata
    Roma, 00133, Italy
  • Policlinico Umberto I
    Roma, 00161, Italy
  • Istituto Clinico Humanitas
    Rozzano, 20089, Italy
  • Emergency Hospital of Dzerzhinsk
    Dzerzhinsk, 606019, Russian Federation
  • S.P. Botkin Moscow City Clinical Hospital
    Moscow, 125284, Russian Federation
  • Nizhniy Novgorod Region Clinical Hospital
    Nizhny Novgorod, 603126, Russian Federation
  • Ryazan Regional Clinical Hospital
    Ryazan, 390039, Russian Federation
  • Saint Petersburg City Hospital #15
    Saint-Petersburg, 123182, Russian Federation
  • Clinical Research Institute of Hematology and Transfusiology
    St-Petersburg, 191024, Russian Federation
  • St.-Petersburg City Clinical Hospital nr 31
    St. Petersburg, 197110, Russian Federation
  • Oncology Dispensary of Komi Republic
    Syktyvkar, 167904, Russian Federation
  • King Fahad Specialist hospital
    Dammam, 15215, Saudi Arabia
  • King Abdulaziz Medical City
    Jeddah, 21423, Saudi Arabia
  • King Faisal Specialist Hospital & Research Center
    Riyadh, 12713, Saudi Arabia
  • Hosp. Univ. Germans Trias I Pujol
    Badalona, 08916, Spain
  • Hosp. Univ. Vall D Hebron
    Barcelona, 08035, Spain
  • Hosp. de La Santa Creu I Sant Pau
    Barcelona, 08041, Spain
  • Inst. Cat. Doncologia-H Duran I Reynals
    Barcelona, 08908, Spain
  • Hosp. Univ. Infanta Leonor
    Madrid, 28031, Spain
  • Centro Integral Oncológico Clara Campal
    Madrid, 28050, Spain
  • Hosp. Univ. Son Espases
    Palma, 7120, Spain
  • Hosp. Clinico Univ. de Salamanca
    Salamanca, 37007, Spain
  • Hosp. Virgen Del Rocio
    Sevilla, 41013, Spain
  • INSELSPITAL, Universitätsspital Bern
    Bern, 3010, Switzerland
  • Hopitaux Universitaires de Geneve
    Geneve, 1205, Switzerland
  • UniversitaetsSpital Zuerich
    Zürich, Switzerland
  • Gulhane Egitim ve Arastirma Hastanesi
    Ankara, 06010, Turkey
  • Dr.Abdurrahman Yurtaslan Oncology Training and Research Hospital
    Ankara, 06200, Turkey
  • Ankara Universitesi Tip Fakultesi
    Ankara, 06590, Turkey
  • Koc Universitesi Hastanesi
    Istanbul, 34010, Turkey
  • Ege Universitesi Tip Fakultesi
    Izmir, 35100, Turkey
  • Dokuz Eylul Universitesi Tip Fakultesi
    Izmir, 35340, Turkey
  • Ondokuz Mayis Universitesi Tip Fakultesi
    Samsun, 55200, Turkey
  • St James Hospital
    Leeds, LS9 7TF, United Kingdom
  • University College London Hospitals
    London, NW1 2BU, United Kingdom
  • Kings College Hospital
    London, SE5 9RF, United Kingdom
  • Royal Victoria Infirmary
    Newcastle Upun Tyne, NE1 4LP, United Kingdom
  • Churchill Hospital
    Oxford, OX3 7LE, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2021; primary completion for Apr 2022, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2020
First posted
Feb 11, 2020
StartEst.
May 6, 2021
Primary completionEst.
Apr 19, 2022
CompletionEst.
Jan 28, 2025
Last update
May 20, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04264806
Collaborators
argenx
Responsible party
Sponsor
First posted
Feb 11, 2020
Start date
May 6, 2021 (estimated)
Primary completion
Apr 19, 2022 (estimated)
Completion
Jan 28, 2025 (estimated)
Last update
May 20, 2022

Study contacts

Janssen Research & Development, LLC Clinical trials
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Azacitidine

Start the discussion